Europe’s largest listed private equity group 3i has appointed former chief executive of Cambridge Antibody Technology Group’s Peter Chambré as its industrialist in residence.
Chambré worked as chief executive of Cambridge Antibody Technology from April 2002 until its acquisition by AstraZeneca in July 2006 for around $1.4 billion. Cambridge Antibody Technology was originally backed by 3i.
Prior to this, Chambré was chief operating officer at NYSE-listed molecular diagnostics company Celera Genomics Group. He was also previously chief executive of LSE-listed medical devices group Bespak.
3i’s spokeswoman said: “3i sees a wider healthcare opportunity and we are looking right across the range.” Chambré will have a European remit, she said.
The firm’s venture capital team invests globally with healthcare one of its preferred sectors. It exited care provider Care Principles two months ago for £270 million. It originally backed the business ten years ago with a seed investment of £1.5 million, increasing its investment over time.